Opinion|Videos|July 16, 2024
Strategies for Optimizing Venetoclax-Based Treatment for Patients with CLL
John N. Allan, MD, provides clinical insights on how appropriate dose ramp-up practices for venetoclax can minimize adverse events and optimize patient outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Explore the logistics and best practices aimed at optimizing therapeutic response, minimizing potential adverse events, and maximizing off-treatment benefits.
- How do you initiate venetoclax therapy in your practice, including titration and management of potential AEs and risk of tumor lysis syndrome?
- What insights/implications do recent real-world data provide?
Advertisement
Related to this article
Pooled results from the phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials confirmed the efficacy of pirtobrutinib in treatment-naive CLL.
A post hoc analysis found similar safety outcomes for fixed-duration regimens containing acalabrutinib/venetoclax across age groups in treatment-naive CLL.
In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Darlifarnib Plus Cabozantinib Displays Early Signals of Safety and Efficacy in RCC
3
Five Under 5: Top Oncology Videos for the Week of 8/16
4
The OncFive: Top Oncology Articles for the Week of 8/16
5